RedHill Biopharma Announces Expected Timeline for DSMB Meeting and Provides...
The second independent Data and Safety Monitoring Board DSMB meeting of the RHB104 Phase III study for Crohns disease MAP US study is planned to be held in late July 2017 and will assess the safety and...
View ArticleActinobac Biomed Inc. Receives Investment To Advance Promising Treatment for...
NEW BRUNSWICK N.J. July 12 2017 PRNewswireUSNewswire Actinobac Biomed Inc. started with an investment from Foundation Venture Capital Group FVCG Inc. an affiliate of New Jersey Health Foundation NJHF...
View ArticleCelltrion Inc 068270 Financial and Strategic SWOT Analysis Review Report...
Celltrion Inc 068270 Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData...
View ArticleIMMUNE Pharmaceuticals Oncology Subsidiary CYTOVIA Announces the Filing of a...
Favorable relapsefree and overall survival in AML patients with persistent leukemic cells Cytovia Inc. Cytovia the oncology subsidiary of Immune Pharmaceuticals Inc. NASDAQIMNP "Immune" or the Company...
View ArticleWorld Food Intolerance Products Market Opportunities Forecasts 2015 2022...
nFood intolerance is an adverse foodinduced reaction that does not involve the immune system. Lactose sugars and gluten are few common ingredients causing food intolerance worldwide. The onset of...
View ArticleJanssen Announces U.S. FDA Approval Of TREMFYA Guselkumab For The Treatment...
HORSHAM Pa. July 13 2017 PRNewswire Janssen Biotech Inc.Janssen announced today that the U.S. Food and Drug Administration FDA has approved TREMFYA guselkumab for the treatment of adults living with...
View ArticleNovartis confirms 5 year data for first and only fullyhuman IL17A inhibitor...
EAST HANOVER N.J. July 14 2017 PRNewswire Novartis a global leader in Immunology & Dermatology confirmed today positive 5 year efficacy and safety results for Cosentyx from a Phase III...
View ArticleSoligenix Inc SNGX Financial and Strategic SWOT Analysis Review Report...
Soligenix Inc SNGX Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData...
View ArticleRedHill Biopharma Announces Last Patient Visit in BEKINDAÂ Phase II Study for...
Topline results are expected in September 2017 The randomized doubleblind placebocontrolled Phase II study is evaluating the safety and efficacy of BEKINDAÂ RHB102 12 mg in 127 U.S. patients with...
View ArticleRedHill Biopharma RDHL Positive Phase III with BEKINDA for gastroenteritis
Edison Investment Research Pharmaceutical & healthcare RedHill Biopharma RedHill BioPharma delivered a flurry of news recently including a major R&D milestone when a Phase III trial with...
View ArticleProvention Bio Inc. Announces Clinical Program Focused on Intercepting and...
LEBANON N.J. and BOSTON July 18 2017 PRNewswire Provention Bio Inc. a clinical stage biopharmaceutical company dedicated to sourcing developing and commercializing novel therapeutics aimed at...
View ArticleSherman Prize Inspiring Excellence in Crohn's and Colitis Announces 2017...
NAPLES Fla. July 19 2017 PRNewswireUSNewswire The Bruce and Cynthia Sherman Charitable Foundation today announced the 2017 recipients of the Sherman Prize. Stephan R. Targan MD Director of the...
View ArticleWalgreens Pfizer & AstraZeneca Executives Join Board of Directors for...
WASHINGTON July 19 2017 PRNewswireUSNewswire Today the National Association of Specialty Pharmacy NASP announced the addition of three new healthcare veterans to its governing board of directors...
View Article72 kDa Type IV Collagenase Matrix Metalloproteinase 2 or Gelatinase A or...
72 kDa Type IV Collagenase Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24 Pipeline Review H2 2017SummaryAccording to the...
View ArticleImmune Pharmaceuticals Provides Update on Plan to Implement a Spinoff of...
Immune shareholders to receive additional pro rata shares in Cytovia Immune Pharmaceuticals NASDAQ IMNP Immune today confirmed it is continuing to structure and pursue a spinoff of Cytovia Inc. Cytovia...
View ArticleColitis Pipeline Review H2 2017 Report Updated 11072017 Prices from USD $2000
Colitis Pipeline Review H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis Pipeline Review H2 2017 provides an overview of the Colitis...
View ArticleGranulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha...
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha CDw116 or CD116 or CSF2RA Pipeline Review H2 2017SummaryAccording to the recently published report 'Granulocyte Macrophage Colony...
View ArticleIntegrin Alpha 4 CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or...
Integrin Alpha 4 CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4 Pipeline Review H2 2017SummaryIntegrin Alpha 4 CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or...
View ArticleTumor Necrosis Factor Receptor Superfamily Member 1A Tumor Necrosis Factor...
Tumor Necrosis Factor Receptor Superfamily Member 1A Tumor Necrosis Factor Receptor 1 or Tumor Necrosis Factor Receptor Type I or p55 or p60 or CD120a or TNFRSF1A Pipeline Review H2...
View ArticleGut microbiota and IBD causation or correlation
Changes in the composition and metabolic function of the gut microbiota have been linked to IBD but a direct causal association has yet to be established in humans. This Review discusses the evidence...
View Article